- PLN37.52m
- PLN34.38m
- PLN22.48m
- 98
- 18
- 13
- 36
Annual income statement for Genomed SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | PAS | PAS | PAS | PAS | PAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 19.7 | 18.8 | 19.9 | 20.5 | 22.5 |
Cost of Revenue | |||||
Gross Profit | 7.2 | 6.61 | 7.78 | 7.81 | 9.6 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 18.6 | 18.3 | 18.6 | 20.1 | 21.2 |
Operating Profit | 1.1 | 0.468 | 1.34 | 0.357 | 1.24 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1.08 | 0.409 | 1.33 | 0.369 | 1.05 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1 | 0.412 | 1.24 | 0.338 | 0.926 |
Net Income Before Extraordinary Items | |||||
Net Income | 1 | 0.412 | 1.24 | 0.338 | 0.926 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1 | 0.412 | 1.24 | 0.338 | 0.926 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.743 | 0.312 | 0.937 | 0.256 | 0.701 |
Dividends per Share |